The therapeutic landscape for inflammatory bowel disease [IBD] is rapidly evolving. Two new biologic drugs, vedolizumab and ustekinumab, have recently entered the marketplace, the first biosimilars have been introduced, and several other agents are at an advanced stage of clinical development. In parallel, therapeutic goals have shifted from symptom control towards mucosal healing and prevention of bowel damage. In the coming years, gastroenterologists will be faced with unprecedented choices when selecting the best treatment for their patients with IBD. In this article, we review existing data on the mechanisms of action, efficacy, and safety of recently approved and late-stage pipeline therapies, and use this information to speculate on the positioning of these drugs, alone or in combination, in therapeutic algorithms for Crohn’s disease and ulcerative colitis.


Integrins, Vascular Cell Adhesion Molecule-1, therapeutic use, IL-23 antagonists, Immunosuppressive Agents, JAK inhibitors, Adverse Effects, Smad7, Therapy, TNF antagonists, Antibodies, Pipeline, Monoclonal, Sphingosine-1 phosphate, Inflammatory Bowel Disease, Algorithms, Cell Adhesion Molecules, IBD, Adrenal Cortex Hormones, Immunoglobulins, Crohn's Disease, Janus kinases, Molecular Targeted Therapy, Drug Therapy, Protein Kinase Inhibitors, Mucoproteins, Ulcerative Colitis

Read More